Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jun 2017

Dong Zhong-Yi, Zhong Wen-Zhao, Zhang Xu-Chao, Su Jian, Xie Zhi, Liu Si-Yang, Tu Hai-Yan, Chen Hua-Jun, Sun Yue-Li, Zhou Qing, Yang Jin-Ji, Yang Xue-Ning, Lin Jia-Xin, Yan Hong-Hong, Zhai Hao-Ran, Yan Li-Xu, Liao Ri-Qiang, Wu Si-Pei, Wu Yi-Long

Abstract excerpt

Purpose: Although clinical studies have shown promise for targeting programmed cell death protein-1 (PD-1) and ligand (PD-L1) signaling in non-small cell lung cancer (NSCLC), the factors that predict which subtype patients will be responsive to checkpoint blockade are not fully understood.Experimental Design: We performed an integrated analysis on the multiple-dimensional data types including genomic,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to Immunotherapy

Share to Programmed Cell Death 1 Receptor

Share to Proteomics

Share to Proto-Oncogene Proteins p21(ras)

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 28039262
DOI: 10.1158/1078-0432.CCR-16-2554

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.PMID 28039262Read ↗

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.Semantic proximity Read ↗

Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis.Semantic proximity Read ↗

Prognostic value of KRAS mutations, TP53 mutations and PD-L1 expression among lung adenocarcinomas treated with immunotherapy.Semantic proximity Read ↗

KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma.Semantic proximity Read ↗

TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.Semantic proximity Read ↗

Clinical and Prognostic Implications of an Immune-Related Risk Model Based on TP53 Status in Lung AdenocarcinomaSemantic proximity Read ↗

P53 and NLR could recognize distinct subtypes of lung adenocarcinoma with high expression of PD-L1 (TPS≥50%) defined by 22C3Semantic proximity Read ↗

TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Exploring the Impact of TP53 Mutation and Wild-Type Status on the Efficacy of Immunotherapy in Non-Small Cell Lung CancerSemantic proximity Read ↗

Comprehensive genetic variant analysis reveals combination of KRAS and LRP1B as a predictive biomarker of response to immunotherapy in patients with non-small cell lung cancerSemantic proximity Read ↗

Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.Semantic proximity Read ↗

KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.